Tecentriq (Atezolizumab) vs Kadcyla (trastuzumab emtansine)
Tecentriq (Atezolizumab) vs Kadcyla (trastuzumab emtansine)
Tecentriq (Atezolizumab) and Kadcyla (Trastuzumab Emtansine) are both targeted therapies used in the treatment of certain types of cancer, but they work in different ways and are used for different indications. Tecentriq is an immune checkpoint inhibitor that works by blocking the PD-L1 protein, which can help the immune system in detecting and fighting cancer cells, and is commonly used in the treatment of non-small cell lung cancer, urothelial carcinoma, and triple-negative breast cancer. Kadcyla, on the other hand, is an antibody-drug conjugate that combines Herceptin (trastuzumab) with a chemotherapy drug, delivering a targeted attack on HER2-positive breast cancer cells while minimizing the impact on normal cells, and is primarily used for the treatment of HER2-positive breast cancer. For someone deciding on which medicine is right for them, it is crucial to determine the specific type of cancer they have, including its molecular markers like PD-L1 expression or HER2 status, as this will directly influence the choice of treatment. It is essential to consult with an oncologist who can provide a personalized recommendation based on the individual's cancer characteristics, overall health, and treatment goals.
Difference between Tecentriq and Kadcyla
Metric | Tecentriq (Atezolizumab) | Kadcyla (trastuzumab emtansine) |
---|---|---|
Generic name | Atezolizumab | Trastuzumab emtansine |
Indications | Urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer | HER2-positive breast cancer |
Mechanism of action | PD-L1 inhibitor, immunotherapy | HER2-targeted therapy, antibody-drug conjugate |
Brand names | Tecentriq | Kadcyla |
Administrative route | Intravenous infusion | Intravenous infusion |
Side effects | Fatigue, nausea, cough, shortness of breath, decreased appetite | Fatigue, liver toxicity, musculoskeletal pain, thrombocytopenia, headache |
Contraindications | History of severe hypersensitivity to atezolizumab or its excipients | History of severe hypersensitivity to trastuzumab, emtansine or its excipients |
Drug class | Monoclonal antibody, PD-L1 inhibitor | Antibody-drug conjugate |
Manufacturer | Genentech (Roche) | Genentech (Roche) |
Efficacy
Tecentriq (Atezolizumab) in Breast Cancer
Tecentriq (Atezolizumab) is an immune checkpoint inhibitor that has shown efficacy in the treatment of triple-negative breast cancer (TNBC), which is a type of breast cancer characterized by the absence of estrogen and progesterone receptors, and the lack of excess HER2 protein. Tecentriq has been approved for use in combination with chemotherapy (nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1, as determined by an FDA-approved test. The approval was based on the results of the IMpassion130 trial, which demonstrated that patients with PD-L1-positive tumors experienced a significant improvement in progression-free survival when treated with the combination of Tecentriq and nab-paclitaxel compared to placebo plus nab-paclitaxel.
Kadcyla (Trastuzumab Emtansine) in Breast Cancer
Kadcyla (trastuzumab emtansine) is an antibody-drug conjugate that combines the HER2-targeting properties of trastuzumab with the cytotoxic agent DM1 (emtansine). Kadcyla is specifically designed for the treatment of HER2-positive breast cancer, which is a type of breast cancer that tests positive for human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. In a metastatic setting, Kadcyla has been shown to significantly improve both progression-free and overall survival in patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane, separately or in combination. The efficacy of Kadcyla in this setting was established in the EMILIA trial.
In addition to its use in metastatic breast cancer, Kadcyla has also been approved for the adjuvant treatment of HER2-positive early breast cancer in patients who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. The KATHERINE trial demonstrated that Kadcyla significantly reduced the risk of breast cancer recurrence or death compared to trastuzumab in this patient population.
Both Tecentriq and Kadcyla represent significant advances in the treatment of specific subtypes of breast cancer. Their efficacy in improving survival outcomes highlights the importance of personalized medicine and the need for targeted therapies in oncology. The use of these drugs is contingent upon the determination of the molecular characteristics of the tumor, such as PD-L1 expression and HER2 status, which guides the appropriate therapeutic strategy for each individual patient.
Regulatory Agency Approvals
Tecentriq
Kadcyla
Access Tecentriq or Kadcyla today
If Tecentriq or Kadcyla are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us